Last reviewed · How we verify

NCT03799380

DRIHNC - Dehydration Reduction in Head & Neck Cancer

Completed NA Last updated 3 November 2021
What this trial tests

NA trial testing Gatorade G2 in Dehydration in 41 participants. Completed in 5 May 2021.

Timeline
5 November 2019
Primary endpoint
5 May 2021
5 May 2021

Quick facts

Lead sponsorCase Comprehensive Cancer Center
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingnone
Primary purposesupportive care
Enrollment41
Start date5 November 2019
Primary completion5 May 2021
Estimated completion5 May 2021
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Case Comprehensive Cancer Center — full company profile →

Who can join

18 and older, any sex, with Dehydration or Head & Neck Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to decrease the rate of visits to the Emergency Department (ED) and Acute Care Clinics (ACC) for dehydration for head \& neck (H\&N) and esophageal cancer patients that are given Gatorade while receiving radiation therapy with or without chemotherapy.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Dehydration

Currently open trials in the same condition.

Other Case Comprehensive Cancer Center trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03799380.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing